Teva Pharmaceuticals, Alembic Pharmaceuticals, and Glenmark Pharmaceuticals have all announced the U.S. launch of generic VESIcare (solifenacin succinate) tablets.
Initially approved for Astellas in 2004, solifenacin succinate is indicated for those suffering from overactive bladder with additional symptoms of urge urinary incontinence, urgency, and urinary frequency, the generic will follow the brand name dosages of 5 mg and 10 mg tablets.
Starting dosage is 5 mg and may only be increased to 10 mg after the patient exhibits signs that they can tolerate the drug.
5 mg is the limiting dosage for patients with severe renal impairment, moderate hepatic impairment, or are concomitantly using potent CYP3A4 inhibitors. Solifenacin succinate is not recommended, but not contraindicated, for patients with severe hepatic impairment.
Solifenacin succinate is contraindicated for patients suffering from urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and those that demonstrate a hypersensitivity to the drug.
Full solifenacin succinate prescribing information can be accessed here.